Organon Joins Biosimilars Forum

Latest Member to Join Premier Forum of Manufacturers Promoting Patient Access to Biosimilars

WASHINGTON, D.C. – The Biosimilars Forum today announced Organon Inc. (NYSE: OGN) as its newest member of the organization as it continues to grow and promote awareness of and access to biosimilar medicines that have the potential to save the U.S. healthcare system billions.

Organon is a global healthcare company formed through a spinoff from Merck (known as MSD outside of the U.S. and Canada) with a focus on women’s health and biosimilars helping to address a spectrum of conditions in the areas of immunology and oncology.

We’re proud to have Organon as our newest member of the Biosimilars Forum. The company’s dedicated focus on biosimilars exemplifies the importance of these options to the U.S. health care system,” said Meaghan Rose Smith, Executive Director of the Biosimilars Forum. “Biosimilars are available for the treatment of serious diseases, and given the state of our healthcare system in the wake of the COVID-19 pandemic, paired with the potential for savings, now is the time for the spotlight to be on biosimilars.

At Organon, we believe in bringing more treatment options to the people who need them,” said Jon Martin, Commercial Leader, US Biosimilars, Organon. “While the policy environment for biosimilars is improving, we know there is a long way to go toward increased access to biosimilars. As a new member of the Biosimilars Forum, we are eager to begin collaborating on our shared goals.

Martin will represent Organon on the Forum’s Board of Directors.

Organon’s new approach to biosimilars encompasses a dedicated biosimilars team focused on delivering patients more options. Organon’s biosimilars team will spearhead education programs for health care providers, payors, and patients to further understanding and access to biosimilars.

Biosimilars Forum members represent the majority of companies with the most significant U.S. biosimilars development portfolios, including Biogen, Boehringer Ingelheim, Coherus BioSciences, Organon, Pfizer, Samsung Bioepis, Sandoz, Teva, and Viatris.

For more information on the Biosimilars Forum, visit or